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Abstract 1 
Inflammation has been proposed as a major component of neurodegenerative diseases 2 
although the precise role it plays has yet to be defined. We have examined the role of key 3 
contributors to this inflammatory process, microglia, the major resident immune cell 4 
population of the brain, in a prion disease model of chronic neurodegeneration. Initially, we 5 
performed an extensive reanalysis of a large study of prion disease, where the 6 
transcriptome of mouse brains had been monitored throughout the time-course of disease. 7 
Our analysis has provided a detailed classification of the disease-associated genes based on 8 
cell type of origin and gene function. This revealed that the genes up-regulated during 9 
disease, regardless of the strain of mouse or prion protein, are expressed predominately by 10 
activated microglia. In order to study the microglia contribution more specifically we 11 
established a mouse model of prion disease in which the 79A murine prion strain was 12 
introduced by an intraperitoneal route into BALB/cJFms-EGFP/- mice, which express Enhanced 13 
Green Fluorescent Protein (EGFP) under control of the c-fms operon.  Samples were taken at 14 
time points during disease progression and histological analysis of the brain and 15 
transcriptional analysis of isolated microglia was carried out. The analysis of isolated 16 
microglia revealed a disease specific, highly pro-inflammatory signature in addition to an up-17 
regulation of genes associated with metabolism and respiratory stress. This study strongly 18 
supports the growing recognition of the importance of microglia within the prion disease 19 
process and identifies the nature of the response through gene expression analysis of 20 
isolated microglia.    21 
 22 
 23 
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Importance 24 
  25 
Inflammation has been proposed as a major component of neurodegenerative diseases.  We 26 
have examined the role of key contributors to this inflammatory process, microglia, the 27 
major resident immune cell population of the brain, in a murine prion disease model of 28 
chronic neurodegeneration.  Our study demonstrates that genes up-regulated throughout 29 
the disease process, are expressed predominately by microglia.  A disease specific highly 30 
pro-inflammatory signature was observed in addition to an up-regulation of genes 31 
associated with metabolism and respiratory stress. This study strongly supports the growing 32 
recognition of the important contribution of microglia to a chronic neurodegenerative 33 
disease process. 34 
 35 
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 39 
Introduction 40 
Over several decades the neuron has been subject to the majority of research into protein 41 
misfolding diseases, but it is now apparent that glial cells are important players in the 42 
neurodegenerative process. Many protein misfolding diseases including Alzheimer’s disease, 43 
Parkinson’s disease and prion diseases demonstrate activation of glial cells in the brain 44 
during the course of disease alongside accumulation of misfolded protein but the precise 45 
role  of the glial cells in the disease process is not known (1-4). Transmission of prion agents 46 
4 
 
to mice provides an excellent model for studying the timing of events during a chronic 47 
process of a neurodegeneration associated with a misfolded protein. The time of inoculation 48 
defines the starting point for the disease process and highly reproducible characteristics of 49 
mouse-adapted prions include accumulation of a misfolded host protein, gliosis, neuronal 50 
loss, distribution of brain lesions and the end point of terminal disease. Activation of glial 51 
cells, both astrocytes and microglia, has been extensively documented as an early event in 52 
the pathogenesis of protein misfolding diseases, occurring well before the onset of clinical 53 
disease (1, 5-7).  54 
 55 
Microglia are the major resident immune cell in the brain and in steady-state are considered 56 
a heterogeneous population with density differences across brain regions (8). They display 57 
region dependant functional signatures, which are enhanced further by age (9). Under 58 
normal conditions microglia adopt a ‘resting’ phenotype where they continually survey their 59 
immediate environment with extended processes (10).   60 
 61 
Following detection of a pathological insult or any disturbance to homeostasis, microglia 62 
adapt their phenotype from ‘resting’ to ‘activated’ whereby they modify both morphology 63 
and biological function (10-12).  Activated microglia have diverse functional phenotypes 64 
dependent on the nature of the stimuli that are not readily apparent from their 65 
morphology, and include a much wider repertoire than the classically defined M1 and M2 66 
phenotypes (13-16).  It has also been proposed that microglia can readily switch from one 67 
phenotype to another (17-19) and are sensitive to peripheral immune system 68 
communication (20-22).  It is also clear that a complicated interconnected network of CNS 69 
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cells contribute to the activated ‘profile’ adopted by microglia with signalling from both 70 
astrocytes and neurons having particular impact (23-26).  71 
 72 
The change of microglia from a resting to an activated state is one of the first pathological 73 
features of prion disease long before there is any evidence of neurodegeneration.  Activated 74 
microglia are widely distributed in the brain and are thought to express low levels of 75 
inflammatory cytokines but high levels of transforming growth factor beta 1 (TGFB1) and 76 
prostaglandin E2 (PGE2) (7, 27).  77 
 78 
This study aims to investigate the role of microglia through detailed analysis of their 79 
morphology and gene expression during the course of prion disease thereby providing new 80 
insights into the pathophysiology of neurodegenerative disease. We have used a prion 81 
disease agent as a model of neurodegeneration and taken an unbiased whole genome 82 
expression analysis approach, which has allowed us to provide an insight into the molecular 83 
processes central to microglia during the neurodegeneration, and highlight how this may 84 
impact disease development. A strong myeloid association was attributed to disease 85 
associated genes identified in our reanalysis supporting the growing recognition of the 86 
importance of microglia within the disease process. To further clarify microglial contribution 87 
we isolated microglia from prion infected mice and analysed their gene expression profile. 88 
 89 
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Material and methods 90 
Reanalysis of Hwang et al. (2009) Data 91 
The Hwang dataset (28) was downloaded from http://prion.systemsbiology.net. Quality 92 
control of these data was performed by Fios Genomics Ltd. (Edinburgh, Scotland) using the 93 
ArrayQualityMetrics (29) and 32 microarrays were removed due to poor quality leaving 386, 94 
both infected and uninfected, for reanalysis. The removal of arrays did not affect the overall 95 
balance of the dataset with a mean average of 2.5 ± 0.08 SE arrays per time point. Data 96 
normalisation was performed using the Robust Multiarray Average (RMA) expression 97 
measure (30).  98 
 99 
Initial inspection of the data showed that there were no age-related trends present in the 100 
control animal data and these were not included in further analyses. Data from prion 101 
infected animals were loaded into BioLayout Express3D (31) and a Pearson correlation matrix 102 
calculated, comparing the expression data from each probeset on the array against all other 103 
probesets (P2/2 pairwise calculations, where P is the number of probesets).  104 
 105 
A threshold of r ≥ 0.75 was used and the resultant correlation graph visualised. To identify 106 
groups of co-expressed genes, the graph was clustered using the graph-based Markov 107 
clustering (MCL) algorithm (32) with the inflation value set at 2.2. The expression profile of 108 
each cluster was inspected, and clusters of genes differentially expressed during disease 109 
were isolated and individual gene profiles examined. Those with an unconvincing profile, i.e. 110 
their expression was weak or unrelated to disease progression, were removed. This left a 111 
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dataset comprising 492 genes in which there was high degree of confidence that their 112 
expression was up-regulated during disease. 113 
 114 
Determination of Cell Type of Origin and Function of Disease-associated Transcripts 115 
Cell origin was determined with reference to existing datasets.  A dataset was compiled 116 
from data derived from a number of published studies and included microglia, macrophage 117 
and osteoclast myeloid populations (33, 34); purified neuronal populations derived from the 118 
cortex (cholecystokinin+ve, cholinergic, layer 5a, layer 5b, layer 6, prepronociceptin+ve); the 119 
striatum (dopamine receptor subtype-1 medium spiny, dopamine receptor subtype-2 120 
medium spiny) and the cerebellum (basket, Golgi, purkinje, stellate, unipolar brush) and 121 
astrocytes, Bergman glia and oligodendrocyte populations (35, 36).   Finally, datasets 122 
derived from macrophage cultures cultured with lipopolysaccharide (LPS) bacterial 123 
endotoxin (37) were included to allow for the identification of those genes associated with 124 
activation of the innate immune system. Following normalisation of the data, the 492 genes 125 
demonstrating differential expression in response to prion disease were identified in the 126 
composite dataset through matching of gene symbols, and incorporated into an expression 127 
file. Within BioLayout Express3D each gene could then be assessed for their expression in 128 
one or more of these cell types.  129 
 130 
Gene ontology enrichment was determined by uploading the Affymetrix chip ID of the 131 
disease-associated genes to the online Ensembl Biomart data mining tool 132 
(ensembl.org/biomart) using the Mus musculus genes dataset (Ensembl Genes 66). Filters 133 
were applied restricting results to the Affymetrix 430 2.0 chip probe sets. To increase 134 
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accuracy for correct selection of function, filters for gene ontology evidence code, domain 135 
and name were applied, with experimental evidence codes preferred. 136 
 137 
Animals and Treatment  138 
Groups of male and female BALB/cJFms-EGFP/- mice, expressing enhanced green fluorescent 139 
protein (EGFP) under control of the c-fms operon (part of the Csfr1 promoter) (38), were sex 140 
matched and housed under standard conditions in groups of three to five. Food and water 141 
access was ad libitum.  All mouse experiments were reviewed and approved by the local 142 
ethical review committee and performed under license from the UK Home Office in 143 
accordance with the United Kingdom Animal (Scientific Procedures) Act 1988. Mice aged at 144 
16 weeks old were challenged by an intraperitoneal (i.p.) route with 0.02 ml of 1% w/v (in 145 
physiological saline) 79A infected or normal brain material (NBr) for control. At time points 146 
35, 100, 150 and 200 days post-inoculation (dpi) mice were sacrificed (9 per group for 147 
immunohistochemical analysis and 4 per group for microglial extraction).  All remaining 148 
mice (12 and 8 per group respectively), were assessed for clinical signs of prion disease from 149 
150 dpi, and incubation times were calculated according to previously described protocols 150 
(39). These mice were sacrificed during terminal disease, or earlier if welfare required. 151 
Tissue sections from these mice were assessed for spongiform degeneration following 152 
previously described procedures by a scientist blinded to experimental design (40). 153 
 154 
Tissue Preparation and Immunohistochemical Analysis  155 
Brains were removed at the selected time points. Those to be used for 156 
immunohistochemistry were perfusion fixed with saline followed by 4% paraformaldehyde 157 
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(PFA), pH 7.4.  Brain tissue was embedded in paraffin and cut into sections (6 μm). Antigen 158 
retrieval was performed in an autoclave at 121°C for 15 min in dH2O and then incubated in 159 
formic acid (98%) for 10 min at room temperature. Endogenous peroxidase was blocked 160 
with 1% H2O2 (Sigma-Aldrich) in methanol for 10 min. All sections were blocked with 161 
serum-free protein block (Dako) or normal goat serum prior to incubation with the primary 162 
antibody. Sections were immunostained with monoclonal antibody (MAb) 6H4 (Prionics) 163 
recognizing residues 143-151 of murine PrP (0.5 µg ml-1) (41).   Negative control slides were 164 
treated overnight with mouse immunoglobulin control (Invitrogen). Antibody binding was 165 
detected with Vector ABC kit (Vector laboratories) and visualized with 3,3,-166 
diaminobenzidine chromogen.  All sections were counterstained with haematoxylin. 167 
Brains for microglia morphology assessment were removed and immersed in 4% PFA for 24 168 
h, rinsed in Hank's balanced salt solution (HBSS) before incubating for a further 24 h in 20% 169 
sucrose solution at 4oC. Tissues were rinsed with HBSS and snap frozen in isopentane at -170 
40oC. Brains for microglial extraction were immersed in cold HBSS prior to processing (see 171 
microglial isolation procedure).  172 
 173 
Quantification of Microglia Morphology/ Phenotype 174 
Frozen brain tissue was sectioned at 25 µm on a freezing block microtome and sequential 175 
sections 300 µm apart were taken for analysis.  Quantification of microglia activation status 176 
was established on cellular aggregation and morphology observed in BALBcJFms-EGFP/- sections 177 
based on the average number of microglia per 0.05 mm2. Images for cell quantification were 178 
captured as a 50 optical slice z-stack at x10 magnification (Zeiss Plan-Neofluar 10x/0.30 179 
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objective) and compiled into a composite image using ImageJ software 1.48a.  180 
Quantification of EGFP cell number was performed using particle analysis within ImageJ. 181 
Microglia radius was performed on x10 Z stack compiled (reporting Z stacks) images taken at 182 
x40 magnification (Zeiss Plan-Neofluar x40 / 1.30 objective) captured from three standard 183 
locations within four brain regions: the dentate gyrus, cerebellum, medulla and thalamus. 184 
There was a minimum of 3 mice per group and additional images were recorded on adjacent 185 
sections if the total number of EGFP expressing microglia was below 50. Euclidean distance 186 
mapping was utilised to quantify changes in morphology and was performed using the 187 
‘region of interest’ function within ImageJ.  188 
 189 
Microglial isolation procedure  190 
Brains harvested for microglial extraction were placed in cold HBSS and diced before 191 
processing immediately. Brains were dissociated using a GentleMACS™ Dissociator (Miltenyi 192 
Biotec) and Neural Tissue Dissociation Kit P (Miltenyi Biotec). The final cell pellet was re-193 
suspended in 16 ml 35% Isotonic Percoll, split between two 15 ml tubes and carefully 194 
overlaid with 5 ml ice cold 0.1% DEPC treated HBSS.  The resulting Percoll gradient was 195 
centrifuged at 400 g for 45 min at 4°C.  The pellets were then suspended and recombined 196 
into a final volume of 5 ml ice cold 0.1 % DEPC treated HBSS.  Cells were pelleted at 400 g 197 
for 5 min at 4°C using no brake, re-suspended in 90 µl ice cold MACs buffer (Miltenyi 198 
Biotec), 10 µl CD11b (microglia) microbeads (Miltenyi Biotec) and incubated at 4°C for 15 199 
min with gentle rotation.  Following incubation with microbeads, the cell suspension was 200 
washed in 1 ml ice cold MACs buffer at 300 g for 5 min at 4°C then re-suspended in 500 µl 201 
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ice cold MACs buffer. Cells were passed through magnetised LS columns (Miltenyi Biotec) 202 
following the manufacturer’s protocol. 203 
 204 
Verification of Microglial Purity 205 
A subset of isolated cells predicted to be microglia were stained with PE anti-mouse CD11b 206 
(Cambridge Bioscience) and APC anti-mouse CD45 (Cambridge Bioscience). Isotype controls 207 
were prepared using PE Rat IgG2b (Cambridge Bioscience) and APC Rat IgG2a (Cambridge 208 
Bioscience) and a subset of unstained cells served both as negative control and verification 209 
of correct BALB/cJFms-EGFP/- genotype. Cell viability was determined using SYTOX® Blue dead 210 
cell stain (Thermofischer Scientific).  All cell samples were analysed on a BD FACS Aria IIIu 4-211 
laser/11 detector cell sorter running BD FACSDiva™ software (BD Biosciences). Subsequent 212 
analysis of FACS data was also performed using Summit v4.3 software (Dako/Beckham 213 
Coulter). 214 
 215 
Microarray Analysis of Isolated Microglia 216 
Isolated microglia cells were treated with TRIzol® Reagent (Life Technologies) according to 217 
manufacturer’s protocol. Total RNA quality was checked on an Agilent 2100 Bioanalyzer. 218 
RNA samples with RIN value of >7.0 were passed as suitable for analysis and two 219 
representative samples at each time-point for control and disease were taken forward for 220 
analysis. RNA processing was handled by Ark Genomics (The Roslin Institute & R(D)SVS). 221 
RNA was converted to amplified double-stranded cDNA containing biotin using the NuGen 222 
Ovation picoSL WTA labelling kit (NuGen). The cDNA samples were hybridised to Affymetrix 223 
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Mouse Gene 1.1 arrays on a GeneTitan instrument (Affymetrix). Data was quality controlled, 224 
RNA normalised and subjected to network analysis as described above. 225 
 226 
Results  227 
The neurodegenerative disease process is associated with an inflammatory response 228 
which is microglial in origin 229 
Initially, we performed a reanalysis of the data produced by Hwang et al. (2009): a 230 
transcriptomics analysis of brains of multiple strains of mice infected with different prion 231 
strains sampled at various stages of disease progression. These analyses were performed 232 
with a view to identifying genes associated with neurodegenerative disease progression. 233 
The Hwang data from diseased animals were analysed within BioLayout Express3D. A 234 
correlation graph was generated using a Pearson threshold of r > 0.75, consisting of 21,550 235 
nodes with 1,253,332 edges (Figure 1A).  Clustering with MCL yielded 416 clusters. Each 236 
cluster represented genes that share a high degree of co-expression. The expression profile 237 
of the majority of the clusters revealed they had an expression profile that was not linked to 238 
the disease process.  Two major clusters of genes did however exhibit an expression profile 239 
that increased with disease progression in all animal/prion strain combinations (Figure 1B). 240 
The largest of these clusters comprised 377 genes and a second contained 115 genes that 241 
were notable for their increased activation in C57/Bl6 models (Figure 1B). Following manual 242 
inspection of all individual profiles, a total of 492 genes associated with prion disease 243 
development were identified (Supplementary Table 1). All genes in each cluster followed a 244 
similar expression profile with an increase in expression starting at approximately half way 245 
through the incubation period.  246 
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 247 
Once disease association was determined, we next attempted to identify the cellular origin 248 
for each of the 492 differentially expressed genes in question. This was done by examining 249 
the expression of the disease-associated genes in the context of a panel of isolated cell 250 
populations. Datasets were sourced from the GNFv3 cell atlas (33, 34), RNA TRAP (35, 36) 251 
and serial macrophage cultures subjected to LPS (37). This revealed that 315 out of the 492 252 
differentially expressed genes were solely or at least predominately expressed by myeloid 253 
populations, thereby indicating the majority were likely expressed by microglia within the 254 
brain. In contrast, 147 of the genes were expressed by multiple cell types, whilst only 30 255 
were found to be specific to astrocytes, oligodendrocytes and neurons collectively (Figure 2). 256 
The original study by Hwang et al., (2009) identified 333 differentially expressed genes. By 257 
overlaying these 333 genes onto our chosen external datasets within BioLayout Express3D it 258 
was found that 158 of the 333 genes were attributed to a myeloid origin.  A further 18 were 259 
attributed to non-myeloid cell types. The remaining genes were classed as generic, implying 260 
the origin could be any cell within the brain and as such do not rule out a microglial 261 
component.    262 
 263 
Histological Analysis of Microglial Activation and PrP Deposition 264 
Following the identification of the predominantly myeloid origin of the prion disease 265 
signature, we chose next to confirm this observation by performing an analysis of microglia 266 
isolated from diseased brains. Our aim was to verify these findings and to obtain a more 267 
detailed analysis of the activation of microglia during disease. To do this we chose a mouse 268 
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passaged prion agent 79A, inoculated into BALB/cJ Fms-EGFP/- mice by an intraperitoneal route 269 
with 0.02 ml of 1% w/v 79A brain homogenate as our model.  270 
 271 
Clinical disease onset occurred 198.5 +/- 1.0 (SEM) dpi with signs including lethargy, hair 272 
unkempt/loss and hunching all reported. Terminal disease occurred 229 +/- 3.6 dpi. 273 
Pathological analysis of the vacuolation in the brain of terminal animals (n=6) confirmed 274 
clinical disease and indicated that vacuolation was widespread by terminal stage of disease 275 
presenting as typical for the 79A prion strain (42, 43). 276 
 277 
PrP deposition assessed by immunohistochemistry using the 6H4 antibody was first 278 
detected in the infected mice at 150 dpi and restricted to the medulla (Figure 3A/B). PrP 279 
assessment at the terminal stage of disease identified heavy accumulation of fine punctate 280 
particles throughout the majority of the brain, strongest in the thalamus and extending into 281 
the medulla. To a lesser extent, deposition was also observed within the hippocampus, but 282 
it was only occasionally found within the cortex. This is the deposition pattern typically 283 
associated with 79A disease progression (42, 44). Microglial activation was observed in the 284 
same areas as PrP deposition at 150 dpi (Figure 3C/D). Microglia in the NBr inoculated 285 
controls demonstrated ramified appearance and greater microglia separation at ~50 µm 286 
(Figure 3E/F). 287 
 288 
Microglia were identified during the course of disease using EGFP expression and a 289 
quantitative analysis performed on their density and radius, as a measurement of 290 
morphological changes typically associated with the activation of microglia. Comparison to 291 
animals that had been inoculated with uninfected NBr homogenate, we observed at 150 dpi 292 
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an approximate 50% (p = 0.029) increase of microglial cell number per 0.05 mm2, within the 293 
medulla of 79A infected mice (Figure 4A). Similarly, at 200 dpi an increase of microglia of 294 
approximately 50% (p = 0.02) was observed within the thalamus. The intercellular distance 295 
of microglial in control and unaffected regions was approximately 70-100 µm, while within 296 
affected regions this was reduced to approximately 25 µm (Figure 4B).  Cellular microglial 297 
activation was also defined by a marked increase in the diameter of the central body while 298 
there is a reduction in the length and number of processes projecting from it (45). An 299 
average length of approximately 30 µm was observed for thalamic microglia at 100 days, 300 
while at 200 dpi this is reduced to an average of 20 µm, indicating morphology associated 301 
with activation.  The reduction in radius is matched with an increase in Euclidean distance 302 
by 1 µm, similar to that seen in the microglia in the thalamus, and indicative of shorter 303 
thicker processes and a larger central body (Figure 4C-E). Thus the pathological analysis 304 
confirmed that microglial activation and PrP disease associated protein deposition occurs by 305 
150 dpi in restricted regions of the brain, and during the course of disease both extend into 306 
multiple brain regions. There was no evidence of either PrP deposition or microglial 307 
activation at 100 days in this model. 308 
 309 
Microglial activation profile  310 
Microglia were isolated at day 35, 100, 150 and 200 dpi from 79A inoculated and control 311 
animals. Isolated cells were stained with CD11b and CD45 fluorochrome conjugated 312 
antibodies and sorted by FACS to confirm purity (Figure 5A-D).  Adult microglia are typically 313 
shown as CD11bHigh and CD45Low (46) and the lower than expected CD11b forward and side 314 
scatter may be attributed to competition for available antigen between the CD11b 315 
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microbeads and CD11b-PE marker.  The number of CD45high cells, indicative of impurities in 316 
the cell isolation process by monocyte contamination, was negligible. Non-specific binding 317 
or auto-fluorescence was not observed.  Cell viability was confirmed as 97% ± 0.43 SE. 318 
Microglia purity was further confirmed from the expression profile of twenty cell-specific 319 
genes representing the main cell groups found within the brain (Figure 5E).  The presence of 320 
CD11bpositive circulating or inflammatory monocytes was confirmed to be absent as 321 
evidenced by the negligible expression of Ly6c or Ccr2 (Supplementary Figure 1). 322 
 323 
The process of isolation did not appear to adversely affect the microglia disease signature.  324 
There was a clear difference between expression profiles of microglia isolated from diseased 325 
mice and those collected from uninfected controls.  Of note was the lack of increased 326 
expression of metabolism genes that may be expected if cells were unduly stressed during 327 
the isolation process.  Staining with SYTOX® Blue also confirmed cells from both infected and 328 
control animals were viable prior to RNA isolation.  Additionally, on a bright field microscope, 329 
isolated microglia presented with a rounded refractive appearance, indicative of healthy 330 
viable cells. 331 
 332 
RNA was extracted and microarray analysis was performed. Following this, the patterns of 333 
gene expression were analysed within BioLayout Express3D.  The expression profile of each 334 
cluster was individually checked to ensure familiarity with the dataset, and those with a 335 
disease associated signature selected.  This resulted in 741 genes that demonstrated an 336 
increase in expression predominately at 200 dpi. The 741 genes were also organised into 2 337 
large clusters which shared a very similar gene expression profile with a clear increase in 338 
expression profile (shown averaged in Figure 6A).  Animals inoculated with NBr material 339 
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showed no significant change in expression throughout the corresponding period. Using the 340 
741 genes of interest, a sample-to-sample (array) level graph within BioLayout Express3D was 341 
generated and confirmed the arrays from the 200 dpi time point had less correlation with 342 
the rest of the samples (Figure 6B). 343 
 344 
Gene Enrichment Analysis 345 
Enrichment analysis of the disease-associated microglial genes using the FuncAssociate 2.0 346 
database (47), confirmed the enrichment (p<0.001) of the following functional gene 347 
descriptions; translation, energy production, immune response, interferon response and cell 348 
stress (Figure 7A). Immunological response comprised the single largest category in respect 349 
to total gene number. The signature included transcripts associated with proteolysis, NFkB-350 
mediated cytokine cascades and innate immunity. The GO enrichment functional groups of 351 
mitochondria, ribosome, cell stress, apoptotic process and proliferation confirmed the 352 
presence of a significant metabolic signature associated with these genes. 353 
 354 
Gene ontology was performed for each gene using the data made available on the Ensembl 355 
Biomart database to allow for functional associations to be determined (Figure 7B). Just 356 
under two thirds of the 741 identified differentially expressed genes were attributed to 357 
metabolism and the maintenance of homeostasis. The correct determination of 358 
differentially expressed metabolic genes to a specific cell type is only possible through the 359 
type of isolated cell type analysis presented here. Metabolic genes are typically expressed 360 
by all tissue cells types, making identification of the cellular origin from a mixed cell 361 
population impossible. Genes that were related to the immune response comprised just 362 
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under a quarter of the total. The 6% of genes associated with cytoskeletal changes and 363 
migration were classed into their own groups respectively and included genes associated 364 
with membrane reshuffling. This was to be expected as microglia are known to be highly 365 
motile in the healthy brain environment (10). The increased expression of cytokines Il1, Tnfa 366 
and Csf1, but not Il6 or Il10, would suggest the response by microglia is lacking in the full 367 
spectrum of cytokines expected from a classical form of activation via the myeloid 368 
differentiation primary response 88 (MYD88)-dependant pathway (48). Pathway analysis of 369 
this dataset within the Reactome database (49), revealed many of the elements of the 370 
MYD88-independent pathway were represented by the differentially expressed genes 371 
within this study. This is supported by the lack of differential expression of Myd88 (Figure 372 
7C). In addition, Tgfb1 was not found to be differentially expressed by microglia during the 373 
disease process (Figure 7D). Transcripts associated with Tgfb1 signalling, including Smad 374 
anchor for receptor activation (Zfyve9), suppressor-of-cytokine-signalling 3, 4 and 5 (Socs3-375 
5) and ubiquitin specific peptidase 15 (Usp15) were also absent. 376 
 377 
Determination of the sub-cellular component for each gene considered to be associated 378 
with metabolism/homeostasis was performed from data obtained from the Ensembl 379 
Biomart database. This enabled the location of many genes to be plotted onto a cellular 380 
map and further organised by function (Figure 8). The identified cellular components 381 
included a significant increase in expression of genes associated with ribosomes within the 382 
rough endoplasmic reticulum and cytoplasm. Indeed, the bulk of the metabolic genes were 383 
associated with the ribosomes, thereby implying an increase in ribosome numbers and/or 384 
ribosome turnover, or an increase in protein synthesis. Also present was a significant 385 
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concentration of genes associated with proteolysis, including proteasome based 386 
ubiquitination.  387 
 388 
Consistent with the increase in metabolic load were a considerable number of genes 389 
associated with oxidative phosphorylation and energy production in mitochondria, including 390 
subunits for cytochrome-c oxidase, NADH dehydrogenase and lactate dehydrogenases; the 391 
latter associated with breakdown of increased levels of lactate in situations of respiratory 392 
stress (50). Also observed were DNA repair processes including expression of poly(ADP-393 
ribosyl)ation-14 (Parp14); a potent transcriptional regulator and DNA damage-dependant 394 
nuclear protein (51, 52).  395 
 396 
The association of the identified genes of interest with a specific function outside 397 
metabolism/homeostasis was plotted onto a cellular map using ontology data obtained 398 
from the Ensembl Biomart database. This enabled the location of each gene to be 399 
determined and further organised by function (Figure 9). The overall expression profile from 400 
this set of genes is one of robust pro-inflammatory myeloid cell activation. The increased 401 
expression of lysosomal-associated membrane protein, ATPase proton pumps and 402 
numerous lysosomal enzymes including cathepsins, histocompatibility subunits and genes 403 
involved in membrane restructuring, strongly support antigen presentation and are a 404 
hallmark of classically activated innate immune cells. Increased expression of surface marker 405 
transcripts Cd48, Cd86, Ccl8, Cxcl9, Cxcl13, and Tlr2 was also observed and all are typically 406 
associated with a pro-inflammatory classical activation phenotype (16, 53-55). 407 
 408 
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Discussion  409 
The dataset generated by Hwang, et al. (28) is uniquely placed among transcriptome 410 
datasets as it is the first to be fully comprehensive in terms of prion-related disease models, 411 
encompassing as it does multiple prion strains and host backgrounds. Our reanalysis of 412 
these data using a correlation network-based approach in combination with a cell origin 413 
classification system has given a unique, unbiased and informative whole genome approach. 414 
This allows identification not only of a core set of genes involved, but also of cell types 415 
associated with the neurodegenerative disease process. We identified a further 299 disease-416 
associated genes not reported in the original study by Hwang, et al. (28) (Table 1).  The 417 
original analysis focused on defining pathways associated with disease progression, which 418 
speculated a prominent neuronal contribution to the disease signature. However our 419 
reanalysis identified a large proportion of those previously identified genes to be of a 420 
myeloid origin with a strong myeloid association being attributed to 315 out of the 492 421 
disease associated genes.  This supports the growing recognition of the importance of 422 
microglia within the disease process.  To further clarify microglial contribution we isolated 423 
microglia from prion infected mice and analysed their gene expression profile. 424 
 425 
Experimental differences between the current study and that of Hwang, et al. (28) including 426 
route of infection, single cell type analysis and RNA amplification, potentially limit the ability 427 
to directly compare the results of the two studies.  Having said this 107 genes were seen to 428 
be upregulated during disease progression in both studies and were primarily associated 429 
with an innate immune response (Supplementary Figure 1).  We adopted an intraperitoneal 430 
route of infection as a “more natural” route of infection rather than the more commonly 431 
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used intracranial route to ensure that microglial activation was the result of a response to 432 
initial infection entering the CNS environment.  With an intracranial route of infection the 433 
microglial response may be complicated by the injection procedure resulting in what has 434 
been termed as ‘pre-priming’ of microglia (56-58). A peripheral route would also 435 
encapsulate any microglial response to systemic inflammation; observed in prion disease 436 
following a peripheral route of infection (59), but not following an intracerebral route (60). 437 
However both studies arrive at the same conclusion; prion disease is associated with a 438 
chronic inflammatory response with microglia being central to the disease process. 439 
 440 
The increase in levels of Il1b, Tnfa and Csf1 strongly portray the microglial activation profile 441 
as pro-inflammatory and not one of atypical down-regulation or resolution of inflammation 442 
(61). The presence of a significant increase in transcripts involved with proteasome activity 443 
and major-histocompatibility mediated antigen presentation, combined with expression of 444 
Cxcr3 ligand genes, offers a microglia activation state more akin to classically activated 445 
macrophages. That said, the lack of expression of Infγ, Il6 and Il33 by microglia, all well-446 
defined pro-inflammatory cytokines (62-64) suggests an atypical inflammatory response. 447 
Also of note, and crucial to the maintenance of a chronic response to inflammatory 448 
cytokines, was that expression of Nfkb1 remained stable despite an increase in expression 449 
of NFKB1 inhibitors  (Nfκbia, Nfκbib and Nfκbie) which have been shown to inhibit formation 450 
of NFKB1 at the transcription stages (65). 451 
 452 
The inflammatory phenotype typically associated with prion disease has been shown to be 453 
remarkably anti-inflammatory and dominated by the anti-inflammatory growth factor Tgf-454 
β1 following injection by an intracerebral (66) or hippocampal stereotactic route (7, 61). 455 
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Found in the healthy brain, Tgf-β1 is a constitutively expressed protein intricately involved in 456 
microglia homeostasis (67-70). The lack of differential expression of Tgfb1 within this 457 
dataset, suggests a lack of active TGF-β1 mediated signalling as a significant contributor to 458 
the disease response by microglia. There was also lack of significant increase in expression 459 
of Usp15, Zfyve9 or Socs3-5, indicating no increased translocation of SMAD2/3 proteins or 460 
MAPK signalling; core intracellular complexes of the TGF-β1 signalling pathway (67, 71-73). 461 
TGF-β1 is required for the correct function of the blood brain barrier, and is itself unable to 462 
pass (74, 75). This therefore suggests that the increased expression of Tgf-β1 noted in other 463 
studies, is either attributable to the intracerebral inoculation or expressed by another group 464 
of cells from within the CNS.  465 
 466 
 467 
Microglia are known to intricately interact with neurons (76-78), and numerous genes 468 
associated with axon elongation, synapse regulation and neurotransmitter release were 469 
observed to increase in expression within the isolated microglia dataset. This partners the 470 
expression of many axon and synapse genes with microglia and adds them to the growing 471 
body of evidence for microglial involvement in neuron regulation (79-83).  It has been 472 
proposed that microglia kill prion infected neurons in a manner dependent upon the 473 
presence and degree of fibrillarity of misfolded protein (84). This single cell dataset supports 474 
the generation of a neurotoxic response from microglia with increased expression of Il1b, 475 
Tnfa and caspase-4 (Casp4) indicating active processing within caspase-1 mediated 476 
inflammasomes (85-87). Other pro-inflammatory genes found within this dataset, and 477 
reported to be neurotoxic, include matrix metalloproteinase 12 (Mmp12) (88) and 478 
prostaglandin-endoperoxide synthase 2 (Ptgs2) (89). The latter is known to be expressed in 479 
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prion disease (90, 91) and is a target of non-steroidal anti-inflammatory drugs (NSAIDs) used 480 
in clinical trials to treat neurodegenerative diseases by inhibiting prostaglandin synthesis 481 
(92). 482 
 483 
Within this analysis microglia were shown to express a disease signature markedly more 484 
pro-inflammatory than that currently portrayed in the literature for prion disease, and more 485 
akin to other protein-misfolding diseases, notably Alzheimer’s disease, in which microglia 486 
are observed as expressing a repertoire of pro-inflammatory cytokines including Tnfa, Il1b 487 
and Il6 (93-95). The increased expression of cytokines Il1b, Tnfa and Csf1, but not Il6 in this 488 
dataset suggests an activation profile that is specific to prion disease and likely also unique 489 
to the in-vivo environment since co-cultures of microglia and neurons in the presence of 490 
PrP106-126 induces a stereotypic response with CD14 mediated detection of damaged neurons 491 
and increased expression of Il6 (96).  This matches the stereotypic neurotoxic response 492 
observed in co-cultures of neurons in the presence of LPS activated microglia (97).  493 
 494 
Our study demonstrated that genes up-regulated throughout the disease process, are 495 
expressed predominately by microglia.  A disease specific highly pro-inflammatory signature 496 
was observed in addition to an up-regulation of genes associated with metabolism and 497 
respiratory stress. This study strongly supports the growing recognition of the important 498 
contribution of microglia to a chronic neurodegenerative disease process. Protein misfolding 499 
diseases typically have a very long pre-clinical phase in which there is a steady and 500 
progressive increase in misfolded protein deposition, neuroinflammation and synaptopathy 501 
as the disease progresses. Thus an understanding of the contributors to this pre-clinical 502 
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phase provides opportunities for devising early intervention strategies to limit the pathology 503 
before damage becomes irreversible 504 
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Figure Legends 768 
Figure 1 - BioLayout Express3D generated transcript -to-transcript network graph of 769 
selected genes of interest.  770 
A: The list of 492 genes of interest with an expression pattern indicative of disease 771 
association were organised into 2 main clusters within BioLayout Express3D by MCL.  The 772 
green cluster comprising 410 nodes was joined by 29,339 edges indicating a high degree of 773 
co-expression between genes. The smaller purple cluster comprised 67 nodes and 1453 774 
edges.  B: The disease associated gene expression signatures of both clusters, displayed as a 775 
mean expression profile for each strain, revealed an up-regulation at approx. 50% of 776 
incubation period.  The profile was similar for all genes in all mouse/prion combinations.  777 
The smaller purple cluster was expressed highest in BL6 strains resulting in the formation of 778 
a separate cluster. Error bars equate to ± SE. Grey triangles on X-axis indicate the incubation 779 
period between the point of inoculation to cull, some mouse/TSE strains leading to 780 
pathology and death faster than others. 781 
 782 
Figure 2 - Cross reference of the 492 disease associated genes with co-normalised external 783 
datasets within BioLayout Express3D.   784 
Within BioLayout Express3D each gene of interest was classed and coloured as a specific cell 785 
type.  Note how the previously determined MCL clusters are both dominated by myeloid 786 
derived genes (green).  Genes associated with myeloid were divided into two groups based 787 
on sole association with myeloid cell types or in which sole origin could not be determined.  788 
Sole myeloid origin comprised 318 genes or 64% of the gene set.  A total of 146 genes were 789 
associated with multiple cell types found within the CNS.  Here a myeloid component was 790 
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still observed as strongly associated with the group.  Genes assigned to astrocytes, 791 
oligodendrocytes and neurons were each represented by <20 genes. 792 
 793 
 794 
Figure 3 - PrP Deposition and Microglia Activation Assessed by immunohistochemistry 795 
Microglia activation was observed in the same areas as PrP deposition.  A/B: Earliest 796 
accumulation of PrP (6H4) is at 150 dpi in the Medulla.   Microglia can be seen C/D: as 797 
accumulating in the same areas of deposition.   E/F:  Normal Microglia in the thalamus and 798 
medulla respectively of mice challenged with normal brain demonstrate a ramified 799 
appearance and greater separation at ~ 50 µm.   All images representative.  Scale bars 800 
equate to 100 µm. 801 
 802 
 803 
Figure 4 - Software determined quantification of EGFP expressing microglia in 79A infected 804 
BALB/cJFms-EGFP/- mice.  805 
A: Quantification of regional microglia cell number in BALB/cJFms-EGFP/- mice following i.p. 806 
challenge with 79A at 100, 150 and 200 dpi.  EGFP expressing cells were counting using 807 
ImageJ particle analysis function on x10 magnification 25µm Z-stack compiled images each 808 
comprising 50 optical slices. Microglia density increases in the medulla by ~ 50% at 150 dpi 809 
whereupon numbers remain constant in this region as PrP deposition spreads anteriorly.  By 810 
200 dpi microglia density in the thalamus has increased by ~ 100%. B: EGFP expressing 811 
microglia in the thalamus of BALB/cJFms-EGFP/- mice following i.p. challenge with 79A at 150 812 
and 200 dpi.  No difference in the number of EGFP expressing cells was observed in the 813 
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thalamus until 200 dpi when a concentration of reactive microglia spaced less than 25 µm 814 
was observed.  Before 200 dpi microglia were observed in all animals as spaced at 50 - 100 815 
µm and adopt a normal ramified morphology. Scale bars equate to 200 µm. Inset scale bars 816 
equate to 20 µm. C: At 200 dpi, microglia present with an engorged central body and 817 
shortened processes conferring a significant reduction in radius.  D: Euclidean distance 818 
mapping affords a highly sensitive quantification of cell complexity encompassing both cell 819 
body size and process branching.  The reduction in cell radius at 200 dpi is reflected in a 820 
mean Euclidean distance increase of 1 µm.  Distance mapping also detailed a slightly less 821 
complex cell type in the NBr animals.  E: High Resolution image analysis of microglia density 822 
per 0.05 mm2 in the thalamus at 200 dpi revealed an increase of ~ 100%.  † Comprises mean 823 
for all NBr inoculated BALB/cJFms-EGFP/- mice at all serial investigation time points.  ‡ Mean 824 
statistical value determined using t-Test assuming variances determined by f-Test. NS = Not 825 
Significant. A, C-E: error bars equate to ± SE. 826 
 827 
Figure 5 - Purity of isolated microglia was confirmed to be high and extracted RNA was 828 
confirmed to be of workable quality.  829 
A: FACS sample analysis of CD11b microbead purified microglia stained with, and positive 830 
for, CD11b-PE & CD45-APC demonstrate a high purity.  B: Isotope control and C: negative 831 
control show no non-specific binding or auto-fluorescence respectively.  D: Cell viability was 832 
confirmed using SYTOX® live-dead stain.  Inset: Isolated cells are EGFP positive. E: Plot of the 833 
mean expression profile of twenty genes known to be expressed in a cell-specific manner. 834 
The first five are known microglial expressed genes, the remainder are expressed in other 835 
brain cell types. This demonstrates that the expression of non-microglia genes in isolated 836 
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microglial populations is negligible, suggesting a relatively pure microglial population. Error 837 
bars equate to ± SE.  838 
 839 
Figure 6 - BioLayout Express3D analysis of isolated microglia gene expression.  840 
A: Average expression profile of the 2 large clusters produced within BioLayout Express3D by 841 
the 741 genes that demonstrate a differential expression in response to disease. All genes 842 
yielded an increase in expression with a large escalation at 200 dpi in 79A infected mice. 843 
Error bars equate to ± SE. B: Global microarray sample-to-sample transposed BioLayout 844 
Express3D graph of the 741 identified genes of interest.  Prion infected and uninfected pre-845 
200 dpi arrays are highly correlated and organised into one component.  Displaying high 846 
inter-correlation but lower correlation with the rest of the population are the arrays for the 847 
200 dpi infected group.  Note: nodes have been coloured only for clarity and are not 848 
indicative of MCL clustering.    849 
 850 
Figure 7 - Ontological analysis of the microglia activation signature within the 741 genes 851 
of interest.    852 
A: GO enrichment terms determined from the identified 741 differentially expressed genes 853 
using FuncAssociate 2.0 revealed protein translation, respiration, cellular stress and 854 
components of the myeloid immune system to be significantly represented.  All terms have 855 
a P-value of considerably less than 0.001. B: Regulated disease-associated genes allocated 856 
by function.  Using the Ensembl Biomart database the majority of the regulated genes were 857 
ascribed to metabolism and homeostasis.  Genes associated with immune system, for which 858 
differentiation has been included, comprise only a fifth.  This highlights the power of a signal 859 
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cell isolation in correctly determining the association of metabolic genes with a specific cell 860 
type. C: Expression of inflammatory cytokines and transcription factors associated with the 861 
regulation of activation phenotype of microglia. Strong increase in expression of Tnfa and 862 
Il1b, but not cytokines associated with recruitment and escalation toward acquired 863 
immunity imply a disease-specific signature.  D: Nominal and unchanged expression of 864 
Tgfb1 is matched by a lack of expression of downstream transcripts mediated by TGFB1 865 
activity. C-D error bars equate to ± SE. 866 
 867 
Figure 8 - Genes of interest associated with metabolism and homeostasis.   868 
A considerable number of genes with an increase in expression are associated with protein 869 
translation and processing.  The increased metabolic load is reflected in the increase in 870 
expression of genes associated with energy production.  871 
 872 
Figure 9 - Genes of interest associated with immune activation and cell-to-cell signalling.   873 
Genes have been grouped by both function and cellular location.  The signature is one of 874 
robust pro-inflammatory innate immune activation. 875 
 876 
 877 
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GO Ontological 
Annotation 
GO ID P-value 
Gene 
No. 
% Within 
Dataset 
Protein Translation 
• ribosome GO:0005840 6.37 x10-54 72 9.72 
• translation GO:0006412 3.52 x10-26 67 9.04 
• ribosome biogenesis GO:0042254 2.70 x10-12 27 3.64 
• endoplasmic 
reticulum 
GO:0005783 1.11 x10-05 68 9.18 
Energy Production 
• mitochondrion GO:0005739 1.10 x10-13 111 14.98 
• generation of 
precursor metabolites 
and energy 
GO:0006091 1.94 x10-05 21 2.83 
• respiratory chain GO:0070469 1.92 x10-13 19 2.56 
Immune Response 
• lysosome GO:0005764 1.55 x10-12 42 5.67 
• regulation of cytokine 
production 
GO:0001817 1.47 x10-09 38 5.13 
• chemokine receptor 
binding 
GO:0042379 2.20 x10-09 13 1.75 
• regulation of 
locomotion 
GO:0040012 1.03 x10-07 41 5.53 
• endosome GO:0005768 6.35 x10-07 41 5.53 
• cell proliferation GO:0008283 3.00 x10-06 78 10.53 
• I-kappaB kinase/NF-
kappaB cascade 
GO:0007249 8.03 x10-06 19 2.56 
• innate immune 
response-activating 
signal transduction 
GO:0002758 1.38 x10-05 12 1.62 
Interferon Response 
• response to 
interferon-gamma 
GO:0034341 1.32 x10-07 12 1.62 
• response to 
interferon-beta 
GO:0035456 1.60 x10-07 9 1.21 
• response to type I 
interferon 
GO:0034340 8.99 x10-07 7 0.94 
Cell Stress 
• response to stress GO:0006950 2.53 x10-13 138 18.62 
• apoptotic process GO:0006915 5.05 x10-07 82 11.07 
• response to wounding GO:0009611 3.06 x10-06 45 6.07 
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Protein Processing (Inc. Proteasome) 
Cndp2, Cpd, Cuedc2, Cul4b, Derl1, Dnajb14, Erlec1, Fbxw4, 
Isg15, Mmp12, Nedd8, Pfdn1, Pfdn5, Psma7, Psmb1, Psmb2, 
Psmb3, Psmb4, Psmb6, Psmd8, Psme1, Ptpra, Rbx1, Shfm1, 
Spcs1, St14, St8sia6, Tceb1, Tcp1, Ubl5, 
Energy Production 
2700094K13Rik, Acadl, Adap1, Atp5e, Atp5h, Atp5k, Atp5l, 
Cox5b, Cox6a1, Cox6a2, Cox6b1, Cox7a1, Cox8a, Cybb, Cycs, 
Cyp4v3, Fdx1, Glrx5, Gm10136, Grpel1, Higd1a, Higd2a, 
Hsd17b11, Idh1, Ldha, Ldhb, Ndufa1, Ndufa2, Ndufa3, Ndufa4, 
Ndufa6, Ndufb11, Ndufc2, Ndufv3, Prdx4, Romo1, Slc25a4, 
Surf1, Tmx3, Tomm7, Txndc5, Uqcr10, Uqcrb, Uqcrh, Usmg5, 
Vat1, Xdh 
Carbohydrate Metabolism 
Chst1, Chst11, Chst2, Galnt6, Galnt7, Gcnt2, Gfpt1, Gmds, 
Gnpda2, Gnptab, Gyg, Pfkfb3, Pfkl, Pgk1, Pigl, Pigu, Prkar1a, 
Tpi1, 
DNA Binding/Repair  
1200014J11Rik, Apitd1, Dek, Dmrtc1c, Dnmt3a, Dscc1, Eya4, 
Fam50a, Mir29a, Mirn692-2b, Nono, Rps27, Parp14, Pgap1, 
Rlf, Sap30, Trip12, Uba52, Utp3, Xrn2, Zbp1, Zcchc17 
Ion Binding/Transport (membrane) 
4931406C07Rik, Aif1, Anxa4 Anxa5, Asph, 
Atp13a5, Atp1a3, Atp2b1, Calu, Ccdc90a, 
Cmc1, Cox17, Dnlz, Fus, Fxyd5, Gca, 
Gnb2l1, Kctd2, Ndufv1, Nme1, Nucb1, 
Nucb2, rp9, Sdf4, Slc11a2, Ssr4, Tpd52, 
Vwce, Zfp704, Zfp868 
Lipid Processing (membrane) 
Abca1, Acbd6, Acot10 , Anxa3, Aplp2, 
Apob, Apobec1, Apoc1, Apoe, Ch25h, 
Chchd3, Fam167b, Gde1, Gltp, Lrpap1, 
Msr1, Osbpl8, Pcyt1a, Peci, Pld3, Plin2, 
Ppap2a, Ptgfrn, Ptgs2, Ptplad2, Sgpl1, 
Srd5a3, Ttc1, 
Translation 
Eef1b2, Eif1a, Eif2s2, Eif3e, Eif3h, Eif3k, Eif3l, Eif4b, Etf1, Fau, 
Gm6251, Lsm2, Mrpl22, Mrpl34, Mrpl36, Mrrf, Naf1, Oas1g, 
Oasl2, Rpl10a, Rpl11, Rpl12, Rpl13, Rpl13a, Rpl14, Rpl18a, 
Rpl19, Rpl21, Rpl22, Rpl22l1, Rpl26, Rpl27, Rpl27a, Rpl28, 
Rpl3, Rpl31, Rpl32, Rpl35, Rpl35a, Rpl36, Rpl36a, Rpl36al, 
Rpl37, Rpl37a, Rpl38, Rpl39, Rpl39l, Rpl4, Rpl41, Rpl5, Rpl6, 
Rpl7, Rpl8, Rplp0, Rps10, Rps11, Rps12, Rps14, Rps15a, 
Rps15a-ps6, Rps16, Rps17, Rps18, Rps19, Rps2, Rps20, Rps21, 
Rps23, Rps25, Rps26, , Rps27a, Rps27l, Rps29, Rps3, Rps3a, 
Rps4x, Rps5, Rps6, Rps7, Rps8, Sart3, Sec61b, Sec63,  
Transcription  
Bcas2, Churc1, Cic, Cops5, Creb3, Cux1, Ddx1, Drap1, 
Ebna1bp2, Eprs, Exosc9, Fcf1, Hmgn3, Ipo5, Mbd2, Mina, 
Mxd4, Naca, Npat, Phf11d, Prpf6, Ptbp1, Pus3, Rbm42, 
Rpp38, Rtcb, Scand1, Scnm1, Setd3, Snf8, Snord38a, Snrpd3, 
Snrpe, Snrpf, Syncrip, Synj2, Taf10, Taf5l, Tatdn2, Tceb2, 
Trim30a, Utp11l, Utp14a, Yaf2, Znhit1, Znrd1 
Protein Transport (Inc. Vesicular) 
Ap3s1, Arl6ip5, Bst2, Cct2, Chmp1b, Chmp7, Exoc2, Golim4, 
Golph3, Gosr2, Mfsd1, Mmgt2, Mtmr2, Myl6, Nipsnap3b, 
Nup98, Plekha3, Rab1b, Rap2a, Rap2b, Rasgef1b, Rer1, Rtp4, 
Slc23a2, Slc38a6, Slc6a6, Slc7a11, Snap29, Snx17, Snx24, Snx3, 
Srp14, Srp72, Tbc1d22a, Tmed3, Vps28, Vps29, Vti1b, 
General Metabolism 
1700021F05Rik, 1810037I17Rik, 2010107E04Rik, Akr1a4, 
Alas1, Atl2, Azin1, Bhlhb9, Casd1, Dpy19l4, Enpp1, Erbb2ip, 
Evi2a, Extl3, Fam165b, Fam174a, Fundc2, Gm10063, Impad1, 
Lsmd1, Ly6e, Mcee, Mrpl39, Mrpl52, Mrps33, Mrps9, Naa20, 
Naa50, Nd1, Ndufa8, Ndufb2, Ndufb5, Oxct1, Pde4dip, 
Pgam1, Ppm1m, Smpdl3a, Surf4, Tor3a, Vkorc1, Wbp5,  
Figure 8 
Pro-inflammatory Signalling 
1700112E06Rik, 5430435G22Rik, Aggf1, Cd14, Cd200r4, Cd48, 
Cd84, Cd86, Cdc37, Clec5a, Clec7a, Colec12, Csf2rb2, Cxcl10, 
Cxcl16, Cxcr4, Fabp5, Fam20c, Fcgr4, Fgr, Fth1, Ftl1, Ftl2, 
Gadd45a, Gadd45b, Gem, Glipr1, Gng5, Gpr84, H28, H2-D1, 
H2-gs10, H2-K1, H2-Q7, H2-T10, H2-t9, Hcst, Hscb, 
I830012O16Rik, Id2, Ifi202b, Ifi30, Ifi44, Ifih1, Ifit1, Ifit2, Ifit3, 
Ifitm3, Igbp1, Iigp1, Ikbke, Il2rg, Irf1, Irf7, Irf9, Lag3, Lrp12, 
Ly6a, Ly9, Map3k7, Map3k8, Mif, Nkap, Nmi, Ola1, Parp9, 
Ptger4, Robld3, Sdcbp, Slamf9, St5, Stat1, Tapbp, Tlr1, Tlr2, 
Tmem9b, Tnfaip2, Txndc17 
  
Synapse / Axon Function 
Alcam, Apbb2, App, Atxn10, Cadm1, Caprin1, Got1, Grasp, 
Grinl1a, Itga5, Katna1, Krtcap2, Lgals1, Neu1, Nrp1, Plxnb2, 
Sdc3, Sulf2, Syngr1,  
Cytoskeleton 
Arhgap24, Arl2, Arpc1b, Arpc5l, Baiap2, 
Bst2, Capg, Cfl1, Coro1c, Dctn6, Diap2, 
Dtnbp1, Efcab2, Ezr, F2r, Flna, Fmn1, 
Gas2l3, Gpr65, Kif3a, Myo1e, Myo5a, 
Nexn, Nuak2, Plekhh2, Sdc4, Tbca, 
Tmsb10, Tpm4, Ttc30b, Tubb2a, Vim 
  
Complement 
C4b, C3ar1 
  
Redox Stress 
Adh5, Aldoa, Atox1, Cln8, Cops6, Coq7, Cox4i1, Cstb, Gpx4, 
Hif1a, Hspe1, Ifi27l2a, Mapkapk2, Myeov2, Ncf1, Plekha1, 
Ppp1r15b, Prdx1, Prdx5, S100a1, Selm, Serp1, Tacc3, Vac14 
  
Cell Migration & Recruitment 
Ccdc23, Ctnnb1, Hspb11, Itgb1, Lgals3, Lgals3bp, Lox, Lpl, 
Mfap1a, Ninj1, Npnt, Nptn, Plau, Plaur, Postn, Vcam1 
Mitosis/Proliferation 
Anapc13, Ankra2, Bola2, Ccny, Cd180, Cenpc1, Cenpo, 
Cep135, Cetn3, Cfdp1, Cks1b, Dna2, Ecd, Eid1, Gnl3, Hat1, 
Hprt, Impdh2, Mcm3, Mcm6, Mtap4, Npm1, Nus1, Ogfr, Ott, 
Ppp1cc, Ranbp1, Rcc2, Rhoc, Rnaseh2b, S1pr1, Slfn5, Sass6, 
Sssca1, Top2a  
Cytokines & Chemokines 
Ccl4, Ccl5, Ccl8, Ccl9, Ccrl2, Csf1, Cxcl11, Cxcl13, Cxcl14, 
Cxcl16, Cxcl9, Hebp1, Il12b, Il1b, Tnf 
Anti-inflammatory Signalling 
Atp6ap2, Axl, Bag1, Bcl2a1a, Bcl2a1b, Bcl2a1c, Bcl2a1d, Cd274, 
Cd300lf, Cd52, Cd72, Cd83, Cd9, Commd1, Csnk2b, Cst7, Fgl2, 
Hgf, Hint1, Ifi204, Il10rb, Itgax, Klf10, Lilrb4, Milr1, Naip2, 
Nfkbia, Nfkbib, Nfkbie, Rsad2, Serpine2, Slfn2, Spopl, Spp1, 
Tank, Timp2, Tnfaip3, Tpt1, Ubxn1, Usp15, Zc3h12a 
Lysosome Function 
0610031J06Rik, Arrdc4, Asah1, Atp6v0e, 
Atp6v1a, Atp6v1g1, Bloc1s2, Creg1, Ctbs, 
Ctns, Ctsa, Ctsb, Ctsd, Ctse, Ctsh, Ctsl, 
Ctsz, Dpp7, Dram2, Fuca1, Furin, Gaa, 
Galc, Gba, Gla, Glb1, Gm2a, Gns, Gsto1, 
Gusb, Irgm1, Lamp1, Lamp2, Lyst, Lyz2, 
Npc2, Rab12, Rilpl2, Rnf128, Rnf13, 
Rragc, Sqstm1 
Apoptosis (Pro & Anti) 
1110007C09Rik, Adar, Casp4, Ctla2a, Dusp2, Eif2ak2, Fam32a, 
Fnip2, Gabarapl1, Ghitm, Ngfrap1, Niacr1, Pdcd5, Pdcd6, 
Rassf4, Sp100, Stk3, Tmem49  
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